Do you want to read an article? Please log in or register.
Cutoff points for sedentary behavior and their capacity to predict mortality in individuals with COPD: A 12- year follow-up study
Further Publications
Related content
COPD
Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respirology
Pott H, Weckler B, Gaffron S, Martin R, Maier D, Alter P, Biertz F, Speicher T, Bertrams W, Jung AL, Laakmann K, Heider D, Wouters M, Vogelmeier CF, Schmeck B, COSYCONET Study Group
doi: 10.1111/resp.14843
COPD
Mortality and exacerbation risk according to GOLD and STAR severity stages of COPD: a 5-year multicenter prospective cohort study
Sci Rep
Ogata H, Tsubouchi K, Takano T, Ichiki K, Torii R, Takata S, Nakagaki N, Yoshida M, Kitasato Y, Tobino K, Harada E, Wataya H, Ishii H, Maeyama T, Kawasaki M, Fujita M, Yatera K, Zaizen Y, Nakanishi Y, Okamoto I
doi: 10.1038/s41598-025-05033-w
Pulmonary Fibrosis
Severe hepatotoxicity is uncommon following the introduction of Elexacaftor/Tezacaftor/Ivacaftor: A real-world two-years follow-up study of the Danish cystic fibrosis cohort
J Cyst Fibros
Højte C, Olsen MF, Faurholt-Jepsen D, Jørgensen MH, Pressler T, Leo-Hansen C, Bryrup T, Jeppesen M, Olesen HV, Petersen J, Katzenstein TL, Nielsen BU, Skov M, TransformCF Study Group
doi: 10.1016/j.jcf.2025.08.008
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O'Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A
doi: 10.1016/S2213-2600(24)00411-9
Pneumonia
Activities of daily living limitation and functional decline during hospitalization predict 180-day readmission and mortality in older patients with pneumonia: A single-center, retrospective cohort study
Respir Med
Yamada K, Iwata K, Yoshimura Y, Ota H, Oki Y, Mitani Y, Oki Y, Yamada Y, Yamamoto A, Ono K, Kitai T, Tachikawa R, Tomii K, Kohara N, Ishikawa A
doi: 10.1016/j.rmed.2024.107830
Lung Cancer
Site-specific follow-up strategy for surgically resected patients with NSCLC based on ten-year follow-up data
Lung Cancer
Zhang M, Deng C, Fu F, Li Y, Zhang Y, Chen H
doi: 10.1016/j.lungcan.2025.108451
RECOMMENDED
COPD
Tracking Real-World Physical Activity in Chronic Obstructive Pulmonary Disease Over One Year: Results from a Monocentric, Prospective, Observational Cohort Study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Int J Chron Obstruct Pulmon Dis
Boesch M, Baty F, Bilz S, Brutsche MH, Rassouli F
doi: 10.2147/COPD.S469984
RECOMMENDED
COPD
Comparison of clinically meaningful improvements following center-based and home-based tele rehabilitation in people with COPD
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest
Cox DNS, McDonald DC, Burge DAT, Hill DCJ, Bondarenko MJ, Holland PAE
doi: 10.1016/j.chest.2024.11.001